title: Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis.
abstract: We performed a meta-analysis of diarrhea and stomatitis associated with erlotinib use in patients with advanced non-small cell lung cancer. Eligible studies included randomized trials of patients with non-small cell lung cancer on erlotinib describing events of diarrhea and stomatitis. A total of 19 clinical trials including 7524 patients were considered eligible for the meta-analysis. The relative risk of all-grade diarrhea and stomatitis were 2.96 (95% CI: 2.31-3.8; p < 0.00001), 3.62 (95% CI: 2.43-5.39; p = 0.00001), respectively, whereas the relative risk of high-grade diarrhea and stomatitis were 4.65 (95% CI: 3.30-6.55; p < 0.00001), 2.63 (95% CI: 0.83-8.27; p = 0.1), respectively. Our meta-analysis has demonstrated that regimens containing erlotinib for the treatment of advanced non-small cell lung cancer are associated with a significantly increased risk of all-grade diarrhea, stomatitis and high-grade diarrhea. Close clinical monitoring is required when using and administering this drug.
authors: Faculty of Medicine, Clinical Oncology Department, Ain Shams University, Cairo, Egypt.
authors: Omar
authors: O
authors: Abdel-Rahman
authors: Mona
authors: M
authors: Fouad
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D003967:Diarrhea / Q000139:chemically induced* / Q000453:epidemiology; D000069347:Erlotinib Hydrochloride / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013280:Stomatitis / Q000139:chemically induced* / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000069347:Erlotinib Hydrochloride
keywords: NSCLC; diarrhea; erlotinib; meta-analysis; stomatitis